A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After Remission in First-Episode Schizophrenia

Janssen Cilag N.V./S.A0 个研究点目标入组 33 人开始时间: 2015年3月31日最近更新: 2015年4月7日

适应症

试验速览

暂无简介。

•- Participants who completed 24 months RIS-PSY-301 study
•- Surgically sterile female participants or practicing an effective method of birth control before entry and throughout the study; and must have shown a negative urine serum pregnancy test at baseline before study entry
•- Participants who have signed informed consent document
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 33
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 33
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Participants requiring treatment with mood stabilizers or antidepressants at study entry
•- Participants with evidence of alcohol or drug abuse or dependence (except for nicotine and caffeine dependence) according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria diagnosed in the last month before entry
•- Participants with a history of severe drug allergy, drug hypersensitivity, or neuroleptic malignant (cancerous) syndrome
•- Participants with known hypersensitivity to risperidone
•- Participants with acute risk of suicide at study entry or a history of suicidal attempt(s)

发起方

Janssen Cilag N.V./S.A